Skip to main content
BIIB
NASDAQ Life Sciences

Biogen Completes $5.3 Billion Acquisition of Apellis Pharmaceuticals, Secures $2 Billion Term Loan

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$213.49
Mkt Cap
$30.196B
52W Low
$119.18
52W High
$205.97
52W Position info
79% above low
Off High info
at 52W high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

BIIB sits 79% above its 52-week low of $119.18.

Summary

Biogen has completed its $5.3 billion acquisition of Apellis Pharmaceuticals, adding key commercial products and securing a $2 billion term loan to help finance the deal.


Key Events · M&A and Partnerships · BIIB

  • Acquisition of Apellis Pharmaceuticals Completed

    Biogen finalized the acquisition of Apellis Pharmaceuticals for approximately $5.3 billion in cash, plus contingent value rights (CVRs) for up to $582 million based on SYFOVRE® net sales.

  • $2 Billion Term Loan Secured

    Biogen entered into a $2 billion unsecured term loan facility (split into a 364-day and a two-year tranche) to fund a portion of the acquisition consideration.

  • Strategic Portfolio Expansion

    The acquisition adds commercialized products EMPAVELI® and SYFOVRE®, expected to bolster near-term growth and be accretive to non-GAAP diluted EPS by 2027.

  • Contingent Value Rights (CVRs) Issued

    Former Apellis shareholders received non-transferable CVRs, entitling them to potential cash payments of up to $4.00 per CVR upon achievement of specific annual net sales milestones for SYFOVRE® by 2031.


Analysis · BIIB · Life Sciences

Biogen has finalized its acquisition of Apellis Pharmaceuticals for approximately $5.3 billion in cash, plus contingent value rights (CVRs) worth up to an additional $582 million based on future SYFOVRE® sales. This major transaction, previously announced, significantly expands Biogen's portfolio with two commercialized products, EMPAVELI® and SYFOVRE®, and is expected to be accretive to non-GAAP diluted EPS by 2027. To fund a portion of the acquisition, Biogen secured a $2 billion unsecured term loan. The completion of this acquisition marks a significant strategic move for Biogen, aiming to bolster its near-term growth and expand into nephrology.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 52.1% of the 217 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BIIB was trading at $213.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.2B. The 52-week trading range was $119.18 to $205.97. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BIIB - Latest Insights

BIIB
Nov 09, 2026, 1:02 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $248.35
Real-time Price: $253.40 info
Change: +$5.05 (+2%) info
Market Cap: $37.458B info
BIIB
Oct 28, 2026, 6:23 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $252.73
Real-time Price: $253.40 info
Change: +$0.670 (+0.27%) info
Market Cap: $37.458B info
BIIB
Oct 28, 2026, 6:07 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $252.73
Real-time Price: $253.40 info
Change: +$0.670 (+0.27%) info
Market Cap: $37.458B info
BIIB
Oct 28, 2026, 6:00 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $252.73
Real-time Price: $253.40 info
Change: +$0.670 (+0.27%) info
Market Cap: $37.458B info
BIIB
Oct 02, 2026, 11:20 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $221.12
Real-time Price: $253.40 info
Change: +$32.28 (+15%) info
Market Cap: $37.458B info